Abstract
The Hypertension in the Very Elderly Trial (HYVET) randomized 3, 845 patients aged 80 years and older, mean age 83.6 years, with a systolic blood pressure (SBP) of ≥ 160 mmHg to indapamide plus perindopril if needed versus double-blind placebo [1]. The target SBP reached was 150 mmHg, and the lowest SBP reached was 143 mmHg. Median follow-up was 1.8 years. Compared to patients randomized to placebo, patients randomized to antihypertensive drug therapy had a 30% reduction in fatal or nonfatal stroke, a 39% reduction in fatal stroke, a 21% reduction in all-cause mortality, a 23% reduction in cardiovascular death, and a 64% reduction in heart failure
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
